# Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

> **NCT00413075** · PHASE1 · COMPLETED · sponsor: **Valerio Therapeutics** · enrollment: 121 (actual)

## Conditions studied

- Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** oral belinostat

## Key facts

- **NCT ID:** NCT00413075
- **Lead sponsor:** Valerio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2015-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00413075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00413075, "Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00413075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*